Colorectal cancer (CRC) is increasingly becoming a major health problem as the global number of new cases is estimated to reach 3.2 million in 2040, based on the projection of population growth and aging (
1-
3). Currently, conventional curative options for colon cancer include surgical resection, molecular targeted therapy, and adjuvant radiotherapy or chemotherapy (
3-
5). Thus, it is important to find novel biomarkers and molecular mechanisms that can be employed in the treatment of colon cancer. Accumulating evidence shows that microRNAs (miRNAs) contribute to the development and progression of various cancers (
5). MicroRNAs are small, single-stranded, and noncoding nucleotide sequences that can regulate the expression of specific target genes through translational repression or mRNA degradation (
5,
6). MiRNAs are considered potential valuable biomarkers and therapeutic options for cancer, playing a pivotal role in research and clinical settings (
7-
9). miR-34c-5p is a great example with tumor suppression activity, targeting a myriad of genes related to tumorigenesis and cancer progression (
8,
10). Of note, miR-34c-5p can inhibit tumor growth by upregulating apoptotic genes and downregulating the expression of genes associated with cancer cell proliferation (
9,
10). Previous studies have reported the downregulation of miR-34c-5p in colorectal cancer, which was inversely correlated with tumor growth and metastasis (
10,
11). However, little is known about the mechanism through which the miR-34c-5p exerts its inhibitory effects on colorectal cancer cells.